Answers are grounded in this paper and cite their sources.
BACKGROUND: Serum B-cell maturation antigen (sBCMA) levels have emerged as a potential biomarker for disease monitoring in multiple myeloma (MM) with prognostic value. METHODS: Herein, we evaluated the sBCMA levels in 166 patients with newly diagnosed MM with an Elecsys-based sBCMA assay. RESULTS: Increased sBCMA levels at diagnosis were correlated with inferior survival outcomes in terms of both progression-free and overall survival. In a subset of patients with available samples at the time of disease progression, there was a trend for decreasing sBCMA values. CONCLUSION: Sequential evaluation of sBCMA in prospective studies will determine the value of incorporating sBCMA measurement in clinical practice.
No takes yet. Share an insight, caveat, or question.
Terpos et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: